TY - JOUR
T1 - Perioperative therapies for urological cancers
AU - Inokuchi, Junichi
AU - Yokomizo, Akira
AU - Nishiyama, Naotaka
AU - Kitamura, Hiroshi
AU - Eto, Masatoshi
AU - Nishiyama, Hiroyuki
AU - Tomita, Yoshihiko
N1 - Funding Information:
Junichi Inokuchi and Naotaka Nishiyama have no conflict of interest. Akira Yokomizo receives honoraria from Astellas Pharma Inc., Bayer Co. Ltd. and Sanofi Co. Ltd. Hiroshi Kitamura receives honoraria from Bristol-Myers Squibb and MSD; research funding from AstraZaneca, Bayer and MSD. Masatoshi Eto receives honoraria from ONO, Novartis, Pfizer, Bristol-Myers Squibb, Janssen, MSD and Chugai; research funding from Sanofi, Pfizer, Bayer, Astellas, Kis-sei, Takeda, ONO and Nippon Kayaku. Hiroyuki Nishiyama receives honoraria from Astellas Pharma Inc., MSD, Chugai Pharmaceutical Co., Ltd. and AstraZeneca; research funding from Astellas Pharma Inc. Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd. and ONO Pharmaceutical Co., Ltd. Yoshihiko Tomita receives honoraria from Bristol-Myers Squibb, Chugai, MSD, Novartis, ONO and Pfizer; research funding: Astellas, Chugai, ONO, Pfizer and Takeda.
Publisher Copyright:
© The Author(s) 2020. Published by Oxford University Press. All rights reserved.
PY - 2020/4/1
Y1 - 2020/4/1
N2 - Although surgery with curative intent is critical for management of many localized cancers, multimodal therapy including neoadjuvant and adjuvant therapy has been introduced to increase the effectiveness of local control of surgery and prolong survival. However, strong evidence supporting the utility of such multimodal therapy is limited. The utility of perioperative chemotherapy has been extensively investigated in bladder cancer, and several randomized controlled trials have indicated the benefit of neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Regrettably, perioperative therapy for other urological cancers is controversial; therefore, no definitive conclusions have been drawn. Recently, the number of trials has rapidly increased due to the development of immune checkpoint inhibitors, used alone or in combination with other modalities. In this review, we summarize the current status and supporting evidence for perioperative therapies such as neoadjuvant and adjuvant therapies for urological cancers, including prostate cancer, urothelial cancer and renal cell carcinoma.
AB - Although surgery with curative intent is critical for management of many localized cancers, multimodal therapy including neoadjuvant and adjuvant therapy has been introduced to increase the effectiveness of local control of surgery and prolong survival. However, strong evidence supporting the utility of such multimodal therapy is limited. The utility of perioperative chemotherapy has been extensively investigated in bladder cancer, and several randomized controlled trials have indicated the benefit of neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Regrettably, perioperative therapy for other urological cancers is controversial; therefore, no definitive conclusions have been drawn. Recently, the number of trials has rapidly increased due to the development of immune checkpoint inhibitors, used alone or in combination with other modalities. In this review, we summarize the current status and supporting evidence for perioperative therapies such as neoadjuvant and adjuvant therapies for urological cancers, including prostate cancer, urothelial cancer and renal cell carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=85083546531&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083546531&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyaa013
DO - 10.1093/jjco/hyaa013
M3 - Review article
C2 - 32115649
AN - SCOPUS:85083546531
SN - 0368-2811
VL - 50
SP - 357
EP - 367
JO - Japanese journal of clinical oncology
JF - Japanese journal of clinical oncology
IS - 4
ER -
